18 September 19
Gold & IT stocks best on ground, Energy stocks weigh (CNI, CMA, QAN)
18 September 19
Gold & IT stocks best on ground, Energy stocks weigh (CNI, CMA, QAN)
18 September 19
Income Report: Stepping up and fading the recent move in bond yields – includes portfolio buy-sell alerts (SKI, TCL, FLT, WHC, EHE)
18 September 19
Overseas Wednesday – International Equities & ETF Portfolios (GDX US, NCM, BABA US, TTD US, PSH NA, BAC US, RY CN)
17 September 19
RBA still banging the lower for longer call on rates
17 September 19
Bond yields firm, oil surges should we “run” from growth to cyclicals? (RHC, NCM, BSL, WPL)
16 September 19
Crude spikes, Bellamy’s bid while Sims scraps guidance (BAL, SGM, BHP)
16 September 19
Subscribers questions (BHP, OZL, IIND, MSB, MGG, NCM, ASL, AWC, WSA, HLS)
15 September 19
Market Matters Weekend Report Sunday 15th September 2019
13 September 19
Tech continues to struggle
13 September 19
Does the Healthcare sector look poised to repeat 2018? (CSL, COH, RMD, ANN, PME)
The ASX200 experienced another quiet day at the office finally closing down just -0.14%, overall a pretty good effort considering the US S&P500 fell -0.6% on Friday spooked by fears the Fed will be conservative with their future interest rate cuts. On the sector level, things were relatively quiet with Energy and Resources stocks the standouts in the winner’s circle while Healthcare, Telco’s and Utilities struggled. On the stock level it was the in vogue gold names who again caught my eye with strong gains across board for the majors with Resolute the best gaining +4.6% while heavyweight Newcrest Mining (NCM) traded at its highest level since 2012, finally closing up +2.3% - an impressive session considering gold was trading ~$US20/oz below its Friday high.
We’ve been “waffling” on about a potential rounded top for the ASX200 for around 3-weeks but it remains on track hence there remains no need to change our tune – see orange ellipses on the chart below. Indeed we still favour a break to fresh 2019 highs but with this only being 1.2% away its hardly a big call and really only micro noise that’s best ignored by investors – we simply feel from a risk / reward perspective it’s time to be more defensive, after all it’s not often the market shoots straight up 25%! A number of stocks we’ve mentioned previously including NIB Holdings (NHF) and BHP Group (BHP) look likely to spearhead any advance, although obviously the banks will need to join the party for any market rally to have a realistic chance of surging above the psychological 6800 area.
MM remains comfortable to adopt a more conservative stance over the next 6-months.
NB We are happy to be overweight cash for a few months, especially after the markets rallied 25% BUT not medium-term as history has illustrated that cash is an awful investment vehicle.
Overnight US stocks were firm led by the NASDAQ which rallied +0.9% although the Dow struggled to close positive, gaining just +0.07%. The ASX200 is looking to open up just over 10-points as most begin to focus on reporting season next month.
Today we are going to look at the Healthcare Sector which has delivered both excellent returns and market outperformance post the GFC.
Yesterday MM switched from Healius (HLS) to Adelaide Brighton (ABC) for 2 simple reasons which we have flagged in recent reports:
1 – We sold HLS because of concerns around the business operationally. The takeover we thought might materialise looks to have been at least delayed making this a business we are not keen to own ahead of their upcoming earnings.
2 – We believe that Australia’s largest cement maker ABC is a solid business that is well positioned to benefit from a continued ramp up in infrastructure spend. The stock is still trading over 36% below its 2018 high, at a price which we believe provides good value, especially with its 4.5% fully franked yield.
MM is bullish ABC at current levels initially targeting a test of the $5 area.
Considering the political tensions around Iran we feel it’s been a disappointing performance for the oil bulls over the last few weeks – MM generally believes that a market that cannot rally on good news is a weak market.
However there is a second side to this particular coin with reports that tankers are offloading millions of barrels of Iranian oil into storage tanks at Chinese ports, leading to a huge surplus of crude on the doorstep of the world’s largest user, hence it’s just a matter of time before this oil starts finding its way into China creating oversupply.
MM is neutral crude oil at best.
Crude Oil Chart
In our new Global ETF Portfolio the recent divergence between crude oil and gold might have many thinking that MM would be considering fading the stretched differential between these 2 usually largely correlated commodities, but not today as the underlying fundamentals feel wrong.
While we find it hard to buy gold compared to crude oil after their recent moves, if we were to make a play it would be still buy gold and sell crude oil hence we just sit on our hands.
Even after the recent strong divergence we prefer gold over crude oil.
Crude Oil v Gold Chart
MM’s concerned with the Healthcare Sector
Since we took a ~30% profit on our ResMed (RMD) position back in mid-June our only exposure to this much loved sector had been via Healius (HLS). After we sold Healius yesterday we have no exposure to the sector which makes up a significant 8.7% of the ASX200.
Today we are going to briefly consider both our own and the US Healthcare Sectors plus 3 leading stocks to ascertain whether we believe this is the correct stance at this point in time.
US Healthcare Sector
Firstly the US Healthcare Sector, which is significantly more influential in comparison to our own making up over 15% of the US S&P500, has so far failed to follow the broader index to fresh all-time highs this year, currently sitting ~5% below its 2018 top. If / when the sector manages to break into blue sky territory it’s a move we would be fading, as opposed to buying.
MM is neutral / bearish the US Healthcare Sector at current levels.
S&P500 Healthcare Sector Chart
Australian Healthcare Sector
The local Healthcare Sector experienced its largest correction in over a decade in Q4 of 2018 with the 20.8% aggressive unwind catching many players napping. Our current concerns with the sector are 3-fold as everyone sits comfortably long, regularly quoting the Australian ageing population thesis:
1 – Valuations are very rich in this growth sector which can easily lead to another fast unwind, it feels to us that too many investors are again complacently long.
2 – Momentum traders / investors who we touched on yesterday are understandably likely to again be long the likes of CSL and Cochlear, making these influential stocks vulnerable to a downside correction, but from where is obviously the million dollar question.
3 – At MM we believe the next 10% move for the $A is up which will turn the last 8-year tailwind into a headwind for much of the sector with significant overseas earnings.
Importantly we believe that a number of the companies in this sector remain world class with our issue not their businesses but the price we should be buying their shares to provide value and hence solid risk / reward.
MM believes the sectors sell-off in Q4 of 2018 might be a classic warning to fragilities within the sector. On balance we believe there’s a strong possibility of gaining exposure to the sector at far better levels. i.e.MM went aggressively long the sector into the weakness in Q4 of 2018 and will do so again when value presents itself.
ASX200 Healthcare Sector Chart
At MM one of our core macro views is that the “little Aussie battler” either has, or is looking for, a major low with the next meaningful move a rally towards 80c i.e. a contrarian view that we are also positioned for in our ETF portfolio.
A strong $A is an earnings headwind for much of the local Healthcare sector who enjoy strong income in $US.
Australian Dollar ($A) Chart
3 major local Healthcare stocks
Below is a brief look under the hood of the sector focusing on 3 heavyweights to see if on the stock level our caution feels warranted plus of course whether there any potential needles in the proverbial haystack.
1 CSL Ltd (CSL) $221.81
Blood Plasma goliath CSL has been an amazing success story becoming the 4th largest stock in Australia, with a market cap of $100bn, now only headed by CBA, BHP and Westpac – it makes up over 5% of the ASX200.
Not surprisingly we believe CSL is one of this country’s finest companies with the question being what price to pay for this business which continues to grow courtesy of the demand for its immunoglobulin products. The stock is again almost “priced for perfection” allowing for plenty of scope for disappointment. Since the market downturn around 5-years ago CSL’s average P/E has been around 25x but today its almost 37x, simply too rich for MM. The optimism in the share price is obviously not alone in today’s market which is underpinned by interest rates at their lowest level in history.
MM likes CSL but well below $200.
CSL Ltd (CSL) Chart
2 Cochlear (COH) $216.44
Hearing aid business COH is another high quality business that has provided excellent shareholder returns over the past decade and more. However as the chart below illustrates the stocks very capable of a decent correction and it’s such an event that is currently required to attract MM back to the stock – todays Est P/E for 2019 of 46.5x certainly carries with it plenty of room for disappointment.
At MM we feel that both CSL and COH fit into the basket of stocks that fund managers / investors are comfortable buying at almost any price bringing with it inherent risks i.e. yesterday we referenced the momentum stocks in the US trading as trading around 25% above their usual levels, not a sell signal in itself as they can easily go to 35% but a warning that should be acknowledged.
MM likes COH as a business but were only buyers well below $200.
Cochlear (COH) Chart
3 ResMed (RMD) $17.50
Sleep disorder business RMD reports this week and if its anything like last time hold onto your hat as volatility is about to enter town – their last result led to a 23% plunge in the stock.
This stock has been another excellent performer post the GFC, and especially since 2015, but again with a P/E of 35x we are concerned with how quickly the stock could get rerated on a solid result but one that fails to meet market expectations.
MM likes RMD but well over 10% lower.
ResMed (RMD) Chart
MM likes many companies in the Australian Healthcare sector but at significantly lower levels, we are comfortable to be absent from the sector today and holding cash to provide flexibility to “pounce” if we see volatility / weakness through reporting season.
No change, US stocks feel extremely vulnerable to us at this stage although we need to see a break back below 2950 by the S&P500 to become seriously concerned with the markets health i.e. just around 1.5% lower.
We reiterate that while US stocks have reached our target area they have not yet generated any technical sell signals.
US S&P500 Index Chart
No change again with European indices, we remain cautious European stocks and their tone has become more bearish over the last few weeks.
German DAX Chart
Overnight Market Matters Wrap
· The US equity markets started its week in positive territory, led by the tech. heavy Nasdaq 100 as the earnings season kicks up a notch.
· Crude Oil continues to rise as the tension in the Persian Gulf escalates as reports of Iran claiming to have arrested 17 of its nationals allegedly recruited by the CIA to spy on sensitive nuclear and military sites in the country.
· BHP is expected to outperform the broader market after endings its US session up an equivalent of 0.52% from Australia’s previous close.
· The September SPI Futures is indicating the ASX 200 to open 18 points higher, testing the 6710 level this morning.
Have a great day!
James & the Market Matters Team
Market Matters may hold stocks mentioned in this report. Subscribers can view a full list of holdings on the website by clicking here. Positions are updated each Friday, or after the session when positions are traded.
All figures contained from sources believed to be accurate. Market Matters does not make any representation of warranty as to the accuracy of the figures and disclaims any liability resulting from any inaccuracy. Prices as at 23/07/2019
Reports and other documents published on this website and email (‘Reports’) are authored by Market Matters and the reports represent the views of Market Matters. The MarketMatters Report is based on technical analysis of companies, commodities and the market in general. Technical analysis focuses on interpreting charts and other data to determine what the market sentiment about a particular financial product is, or will be. Unlike fundamental analysis, it does not involve a detailed review of the company’s financial position.
The Reports contain general, as opposed to personal, advice. That means they are prepared for multiple distributions without consideration of your investment objectives, financial situation and needs (‘Personal Circumstances’). Accordingly, any advice given is not a recommendation that a particular course of action is suitable for you and the advice is therefore not to be acted on as investment advice. You must assess whether or not any advice is appropriate for your Personal Circumstances before making any investment decisions. You can either make this assessment yourself, or if you require a personal recommendation, you can seek the assistance of a financial advisor. Market Matters or its author(s) accepts no responsibility for any losses or damages resulting from decisions made from or because of information within this publication. Investing and trading in financial products are always risky, so you should do your own research before buying or selling a financial product.
The Reports are published by Market Matters in good faith based on the facts known to it at the time of their preparation and do not purport to contain all relevant information with respect to the financial products to which they relate. Although the Reports are based on information obtained from sources believed to be reliable, Market Matters does not make any representation or warranty that they are accurate, complete or up to date and Market Matters accepts no obligation to correct or update the information or opinions in the Reports. Market Matters may publish content sourced from external content providers.
If you rely on a Report, you do so at your own risk. Past performance is not an indication of future performance. Any projections are estimates only and may not be realised in the future. Except to the extent that liability under any law cannot be excluded, Market Matters disclaims liability for all loss or damage arising as a result of any opinion, advice, recommendation, representation or information expressly or impliedly published in or in relation to this report not withstanding any error or omission including negligence.
Financial Services Guide
Date prepared: Wednesday, 22 November 2017
Last update: Friday, 23rd April 2019
About this Financial Services Guide (FSG)
This FSG provides you with key information about a range of subscription services offered by:
Marketmatters Pty Ltd (Market Matters) Australian Financial Services Licence No. 488798 ABN (20 137 462 536)
Level 29, Chifley Tower, 2 Chifley Square Sydney 2000
T: 1300 301 868
E: [email protected]
In this FSG, “we”, us” and “our” refer to Market Matters.
Market Matters holds Australian Financial Services Licence No. 488798 (AFSL) and is responsible for any financial services that we provide to you.
This AFSL was issued on 8th September 2016.
The purpose of this FSG is to provide you with information about:
Market Matters operates a website, www.marketmatters.com.au (Website), where customers may, for the payment of a subscription fee, access certain financial information and general advice. In particular, the Website provides:
This FSG relates only to the Website Services.
What financial services we can offer in connection with the Website Services
As holder of AFSL number 488798, in connection with the Website Services we are authorised to provide general financial product advice to both retail and wholesale clients in relation to the following financial products:
The Website Services are comprised of general advice only. That is, none of the advice given on the Website or by provision of the Website Services takes into account any of your objectives, financial situation or needs (Your Personal Circumstances). Before acting on any of the information, advice or Website Services, you must consider the appropriateness of this information in light of Your Personal Circumstances and, if necessary, consult a financial adviser before making any investment decision.
If you are seeking to acquire a specific financial product or security, you should obtain a copy of and consider the Product Disclosure Statement or Prospectus for that product before making any investment decision.
The Website does not provide a trading platform or access to a trading platform. There is no ability to purchase or sell financial products through the Website.
How do I access these services?
You can access these services by going to www.marketmatters.com.au and following the prompts and steps required to sign up for membership. Please read all terms and conditions carefully.
Fees and benefits payable to us and our associates
The Website is a subscription-based service. A yearly fixed subscription fee is payable to Market Matters when you subscribe to the Website which will vary depending on the type of subscription for which you subscribe. At the date of this FSG, the yearly subscription fees are as follows:
Platinum: $1,238 for 12 months
Platinum: $1,993 for 24 months
Subscription fees vary from time to time and are provided on the Website.
The Website does not currently feature third party advertising. Market Matters reserve the right to advertise at a future time for which they may receive remuneration. Any such advertising will be independent of any other content on the Website.
All representatives of Market Matters (Market Matters Staff) receive a salary paid by Market Matters. Market Matters Staff may also receive performance-based bonuses which are based on profitability, the number of subscribers and subscription renewal rates.
How do we manage potential conflicts of interest?
Market Matters have implemented policies and procedures to mitigate the risk of conflicts of interest. These include:
Market Matters Staff and Contributors are encouraged to express independent views and opinions on the topics they write about. This is established through ongoing training, external audits and our conflict of interest and staff trading policies. Market Matters Staff are required to serve the best interests of the subscribers, without consideration of any commercial or personal interests.
How is my personal information dealt with?
If you have a complaint about our services, you should take the following steps:
Contact us and discuss the complaint directly. If you do not feel comfortable discussing the complaint with us or your complaint is not satisfactorily resolved within 2 business days, please telephone Market Matters, on 1300 301 868 and ask to speak with the Complaints Officer. We suggest you put your complaint in writing at this time so that the issues are fully documented and understood by the parties. Your complaint should be addressed to:
The Complaints Officer
Level 29, Chifley Tower,
2 Chifley Square Sydney NSW 2000
Market Matters will review your complaint within 45 days and attempt resolution. If you are still not satisfied with the outcome, you may take your complaint to an external dispute resolution scheme. Market Matters is a member of the scheme operated by the Financial Ombudsman Service. You should write to:Australian Financial Complaints Authority Limited (AFCA)
You may also wish to consult ASIC in relation to your complaint. ASIC’s website contains information on complaining about companies and people and describes the types of complaints handled by ASIC. You can contact ASIC on its free call infoline:
Tel: 1300 300 630 or email [email protected]
We maintain professional indemnity insurance to cover our employees and Authorised Representatives (including us) for the financial services they provide, having regard to the following:
If you require further information about these compensation arrangements please contact us.
Terms and Conditions
This website, www.marketmatters.com.au, is published by Marketmatters Pty Limited (ABN 20 137 462 536) ('Market Matters', 'MM', 'us', 'we', 'our') Australian Financial Services Licence 488798
Financial Services Guide
Market Matters Financial Services Guide (FSG) is located here, and contains important information about the financial services provided by Market Matters. You must read our FSG and consider it in the context of your Personal Circumstances before acting on any advice. By accepting the terms and conditions you are acknowledging that you have read the FSG.
Provision of the Reports
Reports and other documents published on the Market Matter’s website (‘Reports’) are authored by Market Matters. The Reports represent the views of Market Matters based on technical analysis of companies, commodities and the market in general. Technical analysis focuses on interpreting charts and other data to determine what the market sentiment about a particular financial product is, or will be. Unlike fundamental analysis, it does not involve a detailed review of the company’s financial position.
The Reports contain general, as opposed to personal advice. That means they are prepared for multiple distribution without consideration of your investment objectives, financial situation and needs (‘Personal Circumstances’). Accordingly, any advice given is not a recommendation that a particular course of action is suitable for you and the advice is therefore not to be acted on as investment advice. You must assess whether or not any advice is appropriate for your Personal Circumstances before making any investment decisions. You can either make this assessment yourself, or if you require a personal recommendation, you can seek the assistance of a financial advisor.
The Reports are published by Market Matters in good faith based on the facts known to it at the time of their preparation and do not purport to contain all relevant information with respect to the financial products to which they relate. Although the Reports are based on information obtained from sources believed to be reliable, Market Matters does not make any representation or warranty that they are accurate, complete or up to date and Market Matters accepts no obligation to correct or update the information or opinions in the Reports.
If you rely on a Report, you do so at your own risk. Any projections are estimates only and may not be realised in the future. Except to the extent that liability under any law cannot be excluded, Market Matters disclaims liability for all loss or damage arising as a result of any opinion, advice, recommendation, representation or information expressly or impliedly published in or in relation to this report notwithstanding any error or omission including negligence.
Past performance is not a reliable indicator of future results. Brokerage costs have not been included in the calculation of performance. As financial products rise and fall in value, returns may be negative. Performance figures are not intended to be a forecast. Market Matters does not guarantee the performance of or returns on any investment.
Employees and/or associates of Market Matters may hold one or more of the stocks reviewed on this website.
Subscriptions and Subscription Prices
To access premium content available on the Market Matters website you may initially subscribe through the complimentary trial which provides you full access to all services for the trial period. You are limited to two trials after which you must subscribe to one or more membership categories available on the website or direct with Market Matters before you can trial the service again, three months after the expiry of your second trial.
To subscribe to Market Matters services and access to the website you may go to the Memberships page of the website, provide the information marked as ‘Mandatory’ and select the payment option for the price quoted (at the time of your transaction) or contact the team directly at Market Matters by phone or email. You will then receive a verification email from Market Matters indicating that your subscription and payment have been accepted and you will be able to access the premium content.
Prices published on the Market Matters website are quoted in Australian Dollars (AUD) and are inclusive of GST and/or all other duties and taxes. Market Matters has used reasonable endeavours to ensure that prices for subscription to its services are published accurately on the website but these prices are subject to change and Market Matters reserves the right to change these prices and will notify you of any increase by email (with the price increase to apply from the time the next payment is due).
Marketmatters Pty Ltd (ABN 20 137 462 536) will issue a tax invoice to paying subscribers in relation to any supply that is subject to GST in accordance with A New Tax System (Goods and Services Tax) Act 1999.
Any member is entitled to cancel their membership at any time. In the event a member does wish to cancel their subscription, cancellations must be notified in writing to:
Level 29, Chifley Tower, 2 Chifley Square, Sydney NSW 2000
or by email to: [email protected]
All cancellations of month-by-month subscriptions will be cancelled and not billed again the following month.
All cancellations within 14 days we be entitled to a full refund. Any introductory gifts, such as, but not limited to; iPads, Fitbit watches, Apple watches, Google Homes, must be returned in their original condition before a refund will be made.
All cancellations made after 14 days of subscription commencement will not be entitled to a refund unless in the event of extenuating circumstances, at the sole discretion of Market Matters.
Subscriptions will automatically renew on the expiry date of current subscription. In these instances the subscription will be renewed at the current rate published on the Market Matters web site, using the same credit card that paid for the initial subscription, unless otherwise requested by the subscriber. A subscriber who wishes to cancel after being renewed in this way will have a “14 day cooling off period” in which they can request to discontinue and will receive a full refund for the renewal payment, this can be done in writing to:
Level 29, Chifley Tower, 2 Chifley Square Sydney 2000
or by email to: [email protected]
Market Matters has not reviewed any of the websites which link to this website or to which this website links. Market Matters is not responsible for the content of any other website or pages linked to or linking to its website. Following links to any other websites or pages shall be at the user’s own risk.
Copyright © 2018 Marketmatters Pty Ltd (ABN 20 137 462 536). No part of this website, or its content, may be reproduced in any form without the prior consent of Market Matters.
This Agreement is governed by and is to be construed in accordance with the laws of New South Wales, Australia. You agree to the non-exclusive jurisdiction of the courts of New South Wales, Australia in respect of any proceedings concerning this Agreement. This website is not available to US and/or EU persons and by accepting these terms you confirm that you are not a US and/or EU person.